Posted on 20/11/2009 in Pharmaceutical Company Product News Novartis has revealed the results of a study this week, which showed that just half of its vaccine dose for the H1N1 strain could serve to fully protect individuals from the virus.
Half of the approved product was shown to fill the immune response criteria in both adults and those aged 65 and over.
Additionally, a single dose was found to meet serologic protection criteria against the A(H1N1) virus in children aged between three and eight, adults aged 18 to 64 and the elderly.
Now, Novartis is in talks with the Food and Drug Administration and is performing further analyses of the vaccine.
Andrin Oswald, chief executive officer of Novartis Vaccines and Diagnostics, commented: "The vaccines output of our Liverpool, UK-based flu manufacturing facility [...] could be quadrupled if vaccines are adjuvanted."
This news comes after the firm's biological drug Ilaris (canakinumab) was approved for use in the EU last month.
Other news stories from 20/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
